Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancerReport as inadecuate




Goserelin plus endocrine treatments maintained long-term clinical benefit in a male patient with advanced breast cancer - Download this document for free, or read online. Document in PDF available to download.

World Journal of Surgical Oncology

, 12:393

First Online: 23 December 2014Received: 15 March 2013Accepted: 07 April 2014

Abstract

BackgroundGoserelin plus aromatase inhibitors AI have already been used in male advanced breast cancer, but the cases that fulvestrantin male breast cancer are rare.

Case presentationHere we report a case of long-term 3 years response to Goserelin plus continuing endocrine treatments given for a male advanced breast cancer. The patient prolongs his life with high life quality, and has more time with his family.

ConclusionGoserelin plus endocrine treatments may benefit male breast cancer.

KeywordsMale breast cancer Goserelin Endocrine treatment Family time AbbreviationsAIaromatase inhibitors

ERestrogen receptor

PrRprogesterone receptor.

Electronic supplementary materialThe online version of this article doi:10.1186-1477-7819-12-393 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Hang Jiang - Tao Wang - Zefei Jiang

Source: https://link.springer.com/







Related documents